916610-30-5

Basic information

• Product Name: (4-isopropoxy-phenyl)-carbamic acid 4-nitro-phenyl ester
• Synonyms: (4-isopropoxy-phenyl)-carbamic acid 4-nitro-phenyl ester
• CAS NO: 916610-30-5
• Molecular Weight: 316.313
• Mol File: 916610-30-5.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: (4-isopropoxy-phenyl)-carbamic acid 4-nitro-phenyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (4-isopropoxy-phenyl)-carbamic acid 4-nitro-phenyl ester(916610-30-5)
• EPA Substance Registry System: (4-isopropoxy-phenyl)-carbamic acid 4-nitro-phenyl ester(916610-30-5)

Safety Data

• Hazardous Substances Data: 916610-30-5(Hazardous Substances Data)

Upstream product

• 7664-66-6 4-(isopropoxy)aniline 
• 7693-46-1 4-Nitrophenyl chloroformate 

Downstream Products

• 916666-98-3 4-(6-amino-5-formyl-pyrimidin-4-yl)-piperazine-1-carboxylic acid (4-isopropoxy-phenyl)-amide 
• 792899-38-8 N-(4-isopropoxyphenyl)piperazine-1-carboxamide 
• 916666-95-0 4-(4-Isopropoxy-phenylcarbamoyl)-piperazine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS

The invention is directed to aminoquinoline and aminoquinazoline compounds of Formula I: where R1, R2, R3, B, Z, Q, p, q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS

The invention is directed to thienopyrimidines and thienopyridines compounds of Formula I and Formula II: where R1, R3, B, Z, Q, p, q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3, the use of such compounds to reduce or inhibit kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS

The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from aminoquinoline and aminoquinazoline compounds of Formula I′: where R1, R2, R3, B, Z, Q, p, q and X are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.